Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcus Biosciences Announces New Employment Inducement Grants
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcus Biosciences Announces New Employment Inducement Grants
What's Going On With Arcus Biosciences Stock On Wednesday?
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS) Trading Up 5.4% Following Analyst Upgrade
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences: Q4 Beat And Casdatifan's Story So Far
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
Rapid Innovation is Reshaping Oncology: Stocks in Focus
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return
Robert Goeltz II Sells 6,552 Shares of Arcus Biosciences (NYSE:RCUS) Stock
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains?
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets